Clinical Trial Update: Insulin Glargine U300 vs Insulin Degludec U100 in Impact on the Glycaemic and Cardiovascular Factors [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing insulin glargine U300 to insulin degludec U100 assessing glycemic and cardiovascular factors in Type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Insulin Glargine U300 (insulin glargine)
• insulin degludec U100 (insulin degludec U100)

Snippet

Sponsor: University of Split, School of Medicine | Conditions: Diabetes Mellitus, Type 2 | Phase 4 | Status: COMPLETED